In a bold move to combat corruption in the healthcare sector, China’s National Health Commission (NHC) has teamed up with nine other government departments to initiate a year-long crackdown. The campaign aims to target corruption within the country’s medical and healthcare industry, with a focus on key positions within the pharmaceutical field. The NHC unveiled this initiative on Tuesday.
This sweeping anti-corruption effort was sparked by mounting concerns over graft within the healthcare sector. Recent estimates suggest that, since the campaign began in mid-July, around 176 Party secretaries or hospital heads have come under investigation.
The NHC emphasized that combating corruption is integral to advancing the high-quality development of the pharmaceutical industry and enhancing the pharmaceutical governance system. Corrupt practices such as accepting kickbacks, bribery, and profiteering by individuals in pivotal roles have been detrimental to the progress of the pharmaceutical industry. These actions have not only hindered the growth of medical, insurance, and pharmaceutical sectors but have also eroded the well-being of the people.
The one-year campaign will encompass various aspects of the pharmaceutical industry, including production, distribution, sales, usage, and reimbursement. Additionally, it will extend to cover pharmaceutical administrative bodies, industry associations, medical institutions, pharmaceutical enterprises, and medical insurance funds.
Key focal points of the campaign include targeting administrative departments that exploit their authority for personal gain, scrutinizing key personnel in medical and health institutions, and investigating sales representatives dealing in drugs, equipment, and consumables. The campaign also intends to address issues related to social organizations that misuse their administrative influence for self-benefit, illicit practices by pharmaceutical companies during procurement and sales, and medical staff who breach integrity standards.
Reports have emerged about the suspension or delay of certain academic conferences due to the ongoing anti-corruption initiative. The NHC clarified that the campaign seeks to rectify fraudulent academic conferences, fabricated events, and the improper sharing of sponsorship fees.
Experts view this year’s anti-corruption campaign in the healthcare sector as particularly robust and far-reaching compared to previous efforts. Zhong Chongming, a specialist from the China Health Culture Association, stressed the importance of combatting corruption to preserve the integrity of the healthcare system and safeguard patient interests.
As the campaign unfolds, several corruption cases have been exposed on social platforms. One prominent case involves Xu Bo, the director of the cardiac catheterization room at Fuwai Hospital, affiliated with the Chinese Academy of Medical Sciences. Xu is under investigation for suspected serious violations of discipline and law. The NHC, after verifying the information with relevant authorities, clarified that online rumors about Xu accepting bribes of up to 1.2 billion yuan ($165.6 million) are not consistent with the ongoing investigation. The case is ongoing.